Related Experiment Video
Updated: Dec 23, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
COVID-19 and RAS: Unravelling an Unclear Relationship
Damiano D'Ardes1, Andrea Boccatonda1, Ilaria Rossi1
1Clinica Medica Institute, European Center of Excellence on Atherosclerosis, Hypertension and Dyslipidemia, "G. D'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
Abstract:
The renin-angiotensin system (RAS) plays a main role in regulating blood pressure and electrolyte and liquid balance. Previous evidence suggests that RAS may represent an important target for the treatment of lung pathologies, especially for acute respiratory distress syndrome and chronic fibrotic disease. The scientific community has recently focused its attention on angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors and their possible benefit/harms for patients infected by Coronavirus disease (COVID-19) who experience pneumonia, but there are still some doubts about the effects of these drugs in this setting.
Insights
The renin-angiotensin system (RAS) impacts blood pressure and fluid balance. RAS inhibitors are explored for lung diseases like COVID-19 pneumonia, but their benefits and risks remain uncertain.
Area of Science:
- Cardiovascular Physiology
- Pulmonary Medicine
- Pharmacology
Background:
- The renin-angiotensin system (RAS) is crucial for blood pressure and fluid homeostasis.
- RAS modulation is implicated in various lung pathologies, including acute respiratory distress syndrome and fibrosis.
- The role of RAS inhibitors in COVID-19 pneumonia is under active investigation.
Purpose of the Study:
- To review the current evidence on the role of the renin-angiotensin system in lung diseases.
- To evaluate the potential benefits and harms of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors in COVID-19 pneumonia.
Main Methods:
- Literature review of existing studies and clinical evidence.
- Analysis of the physiological mechanisms of RAS in the context of lung injury.
- Examination of data concerning ACE inhibitors and AT1R inhibitors in pneumonia, particularly COVID-19.
Main Results:
- The renin-angiotensin system plays a significant role in cardiovascular and pulmonary functions.
- Evidence suggests potential therapeutic targets within the RAS for lung diseases.
- Uncertainty persists regarding the net effect of ACE inhibitors and AT1R inhibitors in COVID-19 patients with pneumonia.
Conclusions:
- The renin-angiotensin system is a key regulator with implications for lung health.
- RAS-targeting drugs show promise but require further investigation for specific lung conditions.
- Clarifying the safety and efficacy of RAS inhibitors in COVID-19 pneumonia is essential.
More Related Videos
Related Concept Videos
The Ras Gene
Ras is a...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Mechanisms of Retrovirus-induced Cancers
Abnormal Proliferation
Single Nucleotide Polymorphisms-SNPs

